engleski

Ziprasidone Clinical Trials Conducted in Croatia

Ziprasidone is a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. The initial evidence suggests an effective dosage range of 80–160 mgr day. Clinical trials suggests that the drug is an effective antipsychotic intreating the positive and negative symptoms of schizophrenia. Croatian investigators took part in three studies of ziprasidone. The first study was ziprasidone versus risperidone study and this study evaluate comparative efficacy of ziprasidone versus risperidone in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder ZIP-NY-97-033. This 12-week double- blind study evaluated 40, 60, and 80 mg ziprasidone and risperidon bid (N = 34).The second study which we took part was a ZIP-NY-98-035 open extension study evaluatingthe safety and tolerability of oral ziprasidone in the treatment of patients who have successfully completed previous ziprasidone study (N = 22). Ziprasidone was initiated at dose of 40 mgbid for days 1 and 2. Dosage was subsequently adjusted within the range 40–80 mg bid according to clinical status. The third study was ziprasidone versus olanzapine in the treatment of chronic schizophrenia or schizoaffective disorder: a 1-year double blind study ZIP-NY-97-002 (N = 20). Although final analyses is not yet done, we can conclude that our experience with ziprasidone trough above mentioned studies confirms efficacy and safety of ziprasidone.

ziprasidone ; clinical trials ; Croatia

nije evidentirano